BiotechTube

MA09-hRPE

Phase 1/2Completed
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dry Age Related Macular Degeneration

Conditions

Dry Age Related Macular Degeneration

Trial Timeline

Jun 9, 2011 → Aug 19, 2015

NCT ID
NCT01344993

About MA09-hRPE

MA09-hRPE is a phase 1/2 stage product being developed by Astellas Pharma for Dry Age Related Macular Degeneration. The current trial status is completed. This product is registered under clinical trial identifier NCT01344993. Target conditions include Dry Age Related Macular Degeneration.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (5)

NCT IDPhaseStatus
NCT02463344Pre-clinicalCompleted
NCT02445612Pre-clinicalCompleted
NCT01469832Phase 1/2Completed
NCT01345006Phase 1/2Completed
NCT01344993Phase 1/2Completed

Competing Products

20 competing products in Dry Age Related Macular Degeneration

See all competitors
ProductCompanyStageHype Score
CLS-AX + Anti-VEGFClearside BiomedicalPhase 1/2
33
CLS-AX + AfliberceptClearside BiomedicalPhase 2
44
Eylea + ALT-L9AlteogenPhase 1
33
FYB203 2 mg (0.05 mL of 40 mg/mL)Formycon AGApproved
77
FYB201 0.5 mg (0.05 mL of 10 mg/mL)Formycon AGApproved
77
UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Unity BiotechnologyPhase 2
44
DS-7080a + RanibizumabDaiichi SankyoPhase 1
33
Fovista® + bevacizumab + ranibizumab + afliberceptAstellas PharmaPhase 2
52
MA09-hRPEAstellas PharmaPre-clinical
23
volociximabAstellas PharmaPhase 1
33
Avacincaptad PegolAstellas PharmaPhase 1
33
Avacincaptad Pegol + Avastin + Lucentis + EyleaAstellas PharmaPhase 2
52
Avacincaptad PegolAstellas PharmaPhase 1
33
E10030 + ranibizumab + E10030 sham intravitreal injectionAstellas PharmaPhase 3
77
E10030Astellas PharmaPhase 1
33
Basiliximab, Tacrolimus, MMF, Prednisolon + Basiliximab, Tacrolimus, MMF + Tacrolimus, MMF, rATGAstellas PharmaApproved
85
ASP7317 + tacrolimus + trimethoprim-sulfamethoxazole + Acyclovir + NystatinAstellas PharmaPhase 1
33
Sub-retinal transplantation of MA09-hRPE cells + tacrolimus and mycophenolate mofetil + Placebo tacrolimus and mycophenolate mofetilAstellas PharmaPhase 2
52
Avacincaptad Pegol + LucentisAstellas PharmaPhase 2
52
E10030 + bevacizumab or aflibercept + E10030 sham injectionAstellas PharmaPhase 3
77

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85